Inhibition of mTOR by temsirolimus overcomes radio-resistance in nasopharyngeal carcinoma.

Shiyong Huang, Ke Du, Zeng Liu, Jiangping Li

Clinical and experimental pharmacology & physiology 2022 Jul

filter terms:

Radio-resistance is a leading cause of nasopharyngeal carcinoma (NPC) treatment failure and identification of sensitising therapeutic targets is an unmet need to enhance clinical management. Given that the mammalian target of rapamycin (mTOR) signalling confers resistance to cancer therapy, we investigated whether mTOR contributes to radio-resistance in NPC and pharmacological inhibition of mTOR can overcome radio-resistance. We found that mTOR mRNA and protein levels, and phosphorylation of its downstream effector were increased in radio-resistant NPC compared with parental cells. mTOR inhibitor temsirolimus inhibits proliferation and induces apoptosis in a panel of NPC cell lines. Importantly, temsirolimus acts synergistically with radiation and is effective against radio-resistant cells. Using radio-resistant xenograft mouse model, we validated the efficacy of temsirolimus in preventing tumour formation and inhibiting tumour growth. Temsirolimus overcome radio-resistance in NPC via inhibiting mTOR signalling. Our work provides the pre-clinical evidence that the combination of radiation and mTOR inhibitor may be a therapeutic strategy in NPC. Our findings might accelerate the initiation of clinical trials on radio-resistant NPC patients using temsirolimus. © 2022 John Wiley & Sons Australia, Ltd.

Citation

Shiyong Huang, Ke Du, Zeng Liu, Jiangping Li. Inhibition of mTOR by temsirolimus overcomes radio-resistance in nasopharyngeal carcinoma. Clinical and experimental pharmacology & physiology. 2022 Jul;49(7):703-709